Author: Customer Service

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed in the open-label extension for up to one year 100% of elsunersen patients – and none on placebo – had additional improvements, including sleep, motor function, muscle tone and attention No treatment-emergent or serious adverse events related to study drug reported BOSTON, April 06, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with early-seizure onset SCN2A developmental and epileptic...

Ecommerce leader honors the most innovative customers and agency and technology partners for their industry achievements AUSTIN, Texas and SYDNEY, Australia, April 06, 2026 (GLOBE NEWSWIRE) — Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of leading ecommerce platform BigCommerce and data feed optimization leader Feedonomics, today announced the winners of its 2026 APAC Customer and Partner Awards. The awards programs recognize the most innovative and inspiring customers and partners doing big things on the BigCommerce and Feedonomics platforms. “We’re proud to recognise the outstanding achievements of our customers and partners across APAC, who continue to push the boundaries of innovation and deliver meaningful business results,” said Shannon Ingrey, vice president and general...

HONG KONG, April 06, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider with the inspiration to become a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today announced a substantial progress on the construction progress of its AI data center project in Finland. Following the recent formal approval of the building permit, on-site construction activities have commenced, and the project is progressing in accordance with the current development plan.Caption: Construction progress at 3 E Network’s Finland AI data centre site. (Left) Tree felling and site clearance have been completed. (Right) Large excavation equipment has arrived on site, and earthworks...

Vancouver, BC, April 06, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) (“Deep Sea Minerals” or the “Company”), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, is pleased to announce the appointment of John Vonglis as a Strategic Advisor to the Company. John is an experienced government, military, defense, and business professional, having served leadership tenures across a variety of public and private sector offices. He serves also as Chairman of the Strategic Advisory Board and Executive Director of Global Government Affairs for NANO Nuclear Energy Inc., where he advises on growth, governance, and strategy at both the domestic and international levels. John has also held similar senior...

NEWPORT BEACH, Calif., April 06, 2026 (GLOBE NEWSWIRE) — NorthStrive Defense Tech LLC (“NorthStrive Defense Tech”), a wholly-owned subsidiary of PMGC Holdings Inc. (the “Company”) (NASDAQ: ELAB), today announced it has acquired rights to a novel drone technology through an exclusive option agreement (“Option Agreement”) with a corporation. The Option Agreement provides NorthStrive Defense Tech with an exclusive option, within the aerospace and defense technologies field (“Field”), to get an exclusive license as to certain patent rights for U.S. Patent No. 12,291,334, covering a next-generation drone system designed to transport payloads across air and water environments. The option (“Option”) is also for a non-exclusive license in the aerospace and defense technologies field as to certain know-how connected to these patent rights,...

David Bibby, President & CEO of Hypercharge, scheduled to speak at Canada’s largest electrification event VANCOUVER, British Columbia, April 06, 2026 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) (the “Company” or “Hypercharge”), a leading, smart electric vehicle (EV) charging solutions provider and network operator, is pleased to announce its gold sponsorship of the EV & Charging Expo 2026, taking place April 8-9, 2026, at the Enercare Centre in Toronto, ON. This marks Hypercharge’s third consecutive year supporting the event as a sponsor, exhibitor, and main stage panel participant. Hypercharge will attend and exhibit at the event, which brings together business and government leaders and organizations advancing transportation electrification. Hypercharge’s booth will also include a dedicated...

SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada. MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details:Poster Title: Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trialPresenter: Wen-Wei Tsai, Ph.D.,...